

RESEARCH ARTICLE


Standardization of perioperative care facilitates safe discharge by postoperative day five after pancreaticoduodenectomy

Sara K. Daniel , Lucas W. Thornblade, Gary N. Mann[‡], James O. Park, Venu G. Pillarisetty*

University of Washington Department of Surgery, Seattle, WA, United States of America

[‡] Current address: Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America

* vgp@uw.edu



Abstract

Introduction

Pancreaticoduodenectomy is a complex surgical procedure associated with high morbidity and prolonged length of stay. Enhanced recovery after surgery principles have reduced complications rate and length of stay for multiple types of operations. We hypothesized that implementation of a standardized perioperative care pathway would facilitate safe discharge by five days after pancreaticoduodenectomy.

Methods

We performed a retrospective cohort study of patients undergoing pancreaticoduodenectomy 18 months prior to and 18 months following implementation of a perioperative care pathway at a quaternary center performing high volume pancreatic surgery.

Results

A total of 145 patients underwent pancreaticoduodenectomy (mean age 63 ± 10 years, 52% female), 81 before and 64 following pathway implementation, and the groups were similar in terms of preoperative comorbidities. The percentage of patients discharged within 5 days of surgery increased from 36% to 64% following pathway implementation ($p = 0.001$), with no observed differences in post-operative serious adverse events ($p = 0.34$), pancreatic fistula grade B or C ($p = 0.28$ and $p = 0.27$ respectively), or delayed gastric emptying ($p = 0.46$). Multivariate regression analysis showed length of stay ≤ 5 days three times more likely after pathway implementation. Rates of readmission within 30 days (20% pre- vs. 22% post-pathway ($p = 0.75$)) and 90 days (27% pre- vs. 36% post-pathway ($p = 0.27$)) were unchanged after pathway implementation, and were no different between patients discharged before or after day 5 at both 30 days (19% ≤ 5 days vs. 23% ≥ 6 days ($p = 0.68$)) and 90 days (32% ≤ 5 days vs. 30% ≥ 6 days ($p = 0.81$)).

OPEN ACCESS

Citation: Daniel SK, Thornblade LW, Mann GN, Park JO, Pillarisetty VG (2018) Standardization of perioperative care facilitates safe discharge by postoperative day five after pancreaticoduodenectomy. PLoS ONE 13(12): e0209608. <https://doi.org/10.1371/journal.pone.0209608>

Editor: Ryan M. Thomas, University of Florida, UNITED STATES

Received: August 14, 2018

Accepted: December 7, 2018

Published: December 28, 2018

Copyright: © 2018 Daniel et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All raw de-identified data files are available from the figshare database (<https://doi.org/10.6084/m9.figshare.6962948.v1>).

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Conclusions

Standardizing perioperative care via enhanced recovery protocols for patients undergoing pancreaticoduodenectomy facilitates safe discharge by post-operative day five.

Introduction

Pancreaticoduodenectomy (PD) is a complex operation associated with morbidity rates approaching 65%[1–3]. Patients are typically hospitalized for over one week, and often require a stay in the intensive care unit (ICU)[4,5]. Factors which may have contributed to this long length of stay (LoS) include historical emphasis on pancreatic and nasogastric drainage, as well as prolonged post-operative bowel rest[6–10]. With the implementation of enhanced recovery after surgery (ERAS) or "fast track" post-operative pathways in the 1990s, these traditional tenets of post-operative surgical recovery have been challenged[11]. While a majority of ERAS literature has focused on colorectal surgery, recent attempts have been made to translate these principles to other sub-specialties, including hepatopancreatobiliary surgery[12]. Generalized concepts in ERAS pathways focus on multimodal narcotic-sparing pain control, early ambulation, and advancement of diet, and require active participation from patients and providers at all levels[7–10,13–15].

In aiming for timely discharge for our patients, we determined that there were opportunities for refinement of our perioperative care practices. We subsequently convened a multi-disciplinary care team comprised of clinic, operating room, and ward staff to develop a standardized peri-operative PD pathway. In addition to the nurses, advanced practice providers, and physicians who provide care in these settings, stakeholders from physical and occupational therapy, social work, nutrition, and pharmacy were actively involved in discussions. This multidisciplinary team examined the highest available level of evidence to create the pathway that was ultimately implemented by all practitioners[15].

Pre-operative components of the pathway included teaching by clinic nurses emphasizing expected post-operative activity level, which is higher than many patients originally anticipate. Other topics included the gradual return to pre-surgery activity level at home, as well as the importance of adequate nutrition for the healing process. Our clinic staff reviews handouts in person with the patient and family during pre-operative teaching (S1 Fig). Additionally, patients are encouraged to increase their protein intake prior to surgery including arginine rich nutrition shakes 5 days before surgery. (Fig 1). In order to reduce insulin resistance, patients received oral carbohydrate loading two hours prior to surgery. Intra-operative blood glucose levels were monitored and maintained at or below a target of 140 mg/dL[15,16]. Intravenous (IV) fluids in the OR were targeted to a goal of 2mL/kg/hr with an extra 500mL bolus in the first 30 minutes based loosely on the RELIEF protocol[17]. Nasogastric (NG) tubes were not routinely placed intra-operatively (Fig 2). Patients were started on clear liquids on post-operative day (POD) 1 and advanced to regular diet on POD 2 or 3, as tolerated (Fig 3). Criteria used to determine diet advancement included lack of nausea, bloating, or excessive belching, however, this was ultimately a patient-specific clinical decision. IV fluids were targeted at 1mL/kg/hr on POD 0 and 0.5 mL/kg/hr on POD 1 for most patients in balance with a target urine output of at least 25mL/hr. Goal was discontinuation of IV fluids in conjunction with diet advancement on POD 3. Early and frequent mobility is promoted by having physical and occupational therapy staff evaluate patients on POD 1. Patients are assisted to sit at the edge of the bed on the day of surgery and are OOB walking on POD 1 onwards. (Fig 4). Prophylactic

Activities before Surgery		
	Day -14 to -1	Day -1
Clinic Visit	<input type="checkbox"/> Pre-op clinic visit <input type="checkbox"/> Discuss care map with patient and set expectations <input type="checkbox"/> Schedule fl/u visit for ~2 weeks post-op <input type="checkbox"/> Consent signed <input type="checkbox"/> Smoking cessation at least 2-4 weeks prior to surgery <input type="checkbox"/> Provide patient with 2 x 8 oz of apple juice	
Diet	<input type="checkbox"/> IMPACT advanced recovery drink each day for 5 days prior to surgery <input type="checkbox"/> Instruct patient to bring chewing gum to hospital	<input type="checkbox"/> 8 oz of apple juice before midnight <input type="checkbox"/> No solid food after midnight. Clear liquids up to 2 hours before surgery.
Mobility	<input type="checkbox"/> Aim to walk 2 miles/day prior to day of surgery	

Fig 1. Whipple Pre-operative Pathway.

<https://doi.org/10.1371/journal.pone.0209608.g001>

anticoagulation with subcutaneous heparin is instituted preoperatively on the day of surgery and transitioned to daily enoxaparin on POD 3 for a total four-week course [18,19]. All patients had a drain placed intraoperatively in the resection bed with drain and serum amylase levels being checked on POD 1 and 3 to facilitate early drain removal when appropriate. All patients are cleared by nutrition, physical therapy, and occupational therapy prior to discharge with an approximate target of POD 5 (Fig 5). Prior to discharge, a post-operative follow up visit was scheduled for 4 to 14 days after discharge, and patients were provided with clinic and emergency after hours contact information. It is institution policy that all patients receive a

Day 0: Pre and Peri-Operative Milestones			
	Pre-Op	Intra-Op	PACU
Vitals/ Monitoring	<input type="checkbox"/> Check blood glucose and start insulin drip protocol if greater than or equal to 140 mg/dL	<input type="checkbox"/> Check blood glucose hourly and start insulin drip protocol if greater than or equal to 140 mg/dL <input type="checkbox"/> Standard anesthesia management (The goals of perioperative management is to keep patient hemodynamically stable with restricted fluids. Hypotension to be treated with fluid boluses and phenylephrine up to 0.8 mcg/kg/min. Avoid Vasopressin boluses and infusion by all means).	<input type="checkbox"/> Check blood glucose hourly and start insulin drip protocol if greater than or equal to 140 mg/dL <input type="checkbox"/> Incentive Spirometer: 10x/hr while awake daily until discharge
Medications	<input type="checkbox"/> Heparin 5,000 Units SC <input type="checkbox"/> 1,000 mg Acetaminophen <input type="checkbox"/> Gabapentin: <input type="checkbox"/> CrCL > or = 60ml/min = 600mg <input type="checkbox"/> CrCl > or = 30-59ml/min = 300mg <input type="checkbox"/> CrCl > 15-29ml/min = 200 mg <input type="checkbox"/> Do not give if CrCl < 15 ml/min <input type="checkbox"/> Regional technique in addition to general anesthesia, unless fully laparoscopic case <input type="checkbox"/> Thoracic epidural aimed at upper level of incision (tested with 3ml 1.5 % Lidocaine w/ Epi 1:200K) unless Exparel planned or fully laparoscopic case or <input type="checkbox"/> Order Exparel 1.3% (13.3 mg/mL) injectable suspension	<input type="checkbox"/> Start pre-op abx (Levofloxacin) immediately in OR <input type="checkbox"/> 1,000 mg Acetaminophen PO pre-op, then IV <input type="checkbox"/> Surgeon to administer Exparel (long-acting local anesthetic)	<input type="checkbox"/> IV PCA
Labs / Tests / Procedures			<input type="checkbox"/> Labs 1 hr after PACU arrival: CBC & CMP
Fluids	<input type="checkbox"/> If IV in, start LR at 50 ml/hr	<input type="checkbox"/> 2 ml/kg/hr of LR. Give 500 mL LR bolus extra during first 30 min	<input type="checkbox"/> LR at 1 ml/kg/hr (if on insulin drip use D5LR) <input type="checkbox"/> Urine Output: 0.3-0.5 ml/kg/hr
Diet	<input type="checkbox"/> 8 oz apple juice 2 hours before surgery start time (no exceptions for diabetics) <input type="checkbox"/> NPO 2 hours prior to surgery		
Lines / Tubes / Drains		<input type="checkbox"/> Foley (temp-sensing) <input type="checkbox"/> 2 large bore IV (16 gauge) +/- arterial line <input type="checkbox"/> NO routine NGT <input type="checkbox"/> Surgical drain placed intra-op <input type="checkbox"/> Gravity bag <input type="checkbox"/> Bulb suction	<input type="checkbox"/> Continue Foley catheter
Mobility	<input type="checkbox"/> Place portable Sequential Compression Devices (SCDs) in pre-op area	<input type="checkbox"/> SCDs on	<input type="checkbox"/> SCDs on except when ambulating; continue until discharge
Other		<input type="checkbox"/> Heating mattress or blanket + Bair hugger	

Fig 2. Whipple Intra-operative Pathway.

<https://doi.org/10.1371/journal.pone.0209608.g002>

Inpatient Milestones: 7SA Target Post-Op LOS = 3-5 days		
	Day 0	Day 1
Vitals / Monitoring	<input type="checkbox"/> Weigh daily until d/c <input type="checkbox"/> Incentive Spirometer: 10x/hr while awake daily until d/c <input type="checkbox"/> I&O's q8h <input type="checkbox"/> Urine output + vital signs q1h X 2, q2h X 2, then q4h	<input type="checkbox"/> Weigh daily until d/c <input type="checkbox"/> Incentive Spirometer: 10x/hr while awake daily until d/c <input type="checkbox"/> I&O's q8h <input type="checkbox"/> VS q4h
Medications	<input type="checkbox"/> Peri-op beta blocker (resume if h/o BB use or arrhythmia) <input type="checkbox"/> Pantoprazole 40 mg IV daily <input type="checkbox"/> Antiemetics (Ondansetron) <input type="checkbox"/> Insulin drip protocol	<input type="checkbox"/> Heparin 5,000 Units SC q8h <input type="checkbox"/> Pantoprazole 40 mg IV Daily <input type="checkbox"/> Insulin drip protocol (change to SC insulin if < 1 unit/hr for 12 hrs)
Pain <small>Note: APS orders all pain meds except PO/IV acetaminophen</small>	<input type="checkbox"/> 650 mg Acetaminophen PO elixir/tablet q6h scheduled until d/c <input type="checkbox"/> Gabapentin 300 mg PO TID continued through Day 3 <input type="checkbox"/> IV PCA (if pain uncontrolled adjust PCA first PRN)	<input type="checkbox"/> 650 mg Acetaminophen PO elixir/tablet q6h scheduled until d/c <input type="checkbox"/> Gabapentin 300 mg PO TID continued through Day 3 <input type="checkbox"/> Discuss Ketorolac (15 mg q6h x's 24 hrs) or other NSAID with attending for pain if not contraindicated <input type="checkbox"/> Continue IV PCA
Labs / Tests		<input type="checkbox"/> CBC, CMP & serum amylase @ 0500
Fluids	<input type="checkbox"/> Target UOP>25 mL/hr <input type="checkbox"/> D5LR at 1ml/kg/hr (modify for CHF, CKD)	<input type="checkbox"/> Target UOP> 25 mL/hr <input type="checkbox"/> D5LR or LR (isotonic), rate: 0.5 ml/kg/hr (modify for CHF, CKD)
Diet	<input type="checkbox"/> Chew gum after surgery <input type="checkbox"/> Modified Clear Liquid Diet (RN administered – sips of water, ice chips, and meds only) <input type="checkbox"/> Fluid Restriction: <8oz/8hrs at a pace of 30 ml/hr	<input type="checkbox"/> Modified Clear Liquid Diet (RN administered – ok for clears (i.e. broth, jello, gatorade)) <input type="checkbox"/> Fluid Restriction: <8oz/8hrs at a pace of 30 ml/hr
Lines / Tubes / Drains	<input type="checkbox"/> Record drain output q4h	<input type="checkbox"/> Drain amylase @ 0500
Mobility	<input type="checkbox"/> SCDs on except when ambulating; continue until discharge <input type="checkbox"/> Encourage to sit up on edge of bed after last set of post-op VS (usually 6hrs). Obtain orthostatic VS.	<input type="checkbox"/> SCDs on except when ambulating; continue until discharge <input type="checkbox"/> OOB to chair in AM and for all meals (3-4x/day) <input type="checkbox"/> OOB at least 6 hours per day <input type="checkbox"/> Half mile around the unit <input type="checkbox"/> Initial ADLs standing at the sink
Consults / Teaching		<input type="checkbox"/> PT/OT Consults <input type="checkbox"/> Nutrition Consult

Fig 3. Whipple Post-operative Pathway Days 0–1.

<https://doi.org/10.1371/journal.pone.0209608.g003>

discharge follow up phone call 24 to 48 hours after leaving the hospital by a nurse manager who can communicate concerns with the surgical team.

We hypothesized that routine discharge on POD 5 after pancreaticoduodenectomy would be feasible and safe, and that the percentage of patients who were able to reach this milestone would increase after perioperative pathway initiation. We also aimed to examine if there were any particular perioperative variables that were associated with failure to meet goal discharge.

Methods

We performed a retrospective review of consecutive patients undergoing PD between December 1st, 2013 and November 30th, 2016. After obtaining Institutional Review Board approval of our quality improvement project, a single physician performed the chart review of all PDs identified by CPT code. All procedures were performed by one of three surgeons at our institution, all with over 5 years of hepatobiliary practice. The single pylorus-preserving operation performed during the study period was not included due to the rarity of this procedure at our institution. The remainder of operations were classic open PDs with one surgeon performing some of the initial dissection laparoscopically with planned open completion. Patients were categorized into two treatment groups: before pathway implementation (December 1st, 2013 to May 31st, 2015) and after pathway implementation (June 1st, 2015 to November 30th, 2016). Patient demographics, comorbidities, and outcomes including complications were abstracted using National Surgical Quality Improvement Program (NSQIP) templates[20].

Pancreatic duct leak and delayed gastric emptying (DGE) was defined by the ISGPS 2016 and 2007 criteria respectively[21,22]. Serious adverse events were defined as any post-operative

Inpatient Milestones: 7SA Target Post-Op LOS = 3-5 days		
	Day 2	Day 3
Vitals / Monitoring	<input type="checkbox"/> Weigh daily until d/c <input type="checkbox"/> Incentive Spirometer: 10x/hr while awake until d/c <input type="checkbox"/> I&O's q8h <input type="checkbox"/> VS q4h	<input type="checkbox"/> Weigh daily until d/c <input type="checkbox"/> Incentive Spirometer: 10x/hr while awake until d/c <input type="checkbox"/> I&O's q8h
Medications	<input type="checkbox"/> Change from Heparin SC to Lovenox 40 mg SC qHS at 2100 (consult Rx if CKD) <input type="checkbox"/> Change Pantoprazole from IV to PO <input type="checkbox"/> Begin Pancreatic Enzymes (resume if pt was on at home) <input type="checkbox"/> Start Senna 17.2mg PO qHS	<input type="checkbox"/> If >5kg over pre-op weight give Lasix 10 mg IV if renal function adequate
Pain <small>Note: APS orders all pain meds except PO/IV acetaminophen</small>	<input type="checkbox"/> 650 mg Acetaminophen PO elixir/tablet q6h scheduled until d/c <input type="checkbox"/> Gabapentin 300 mg PO TID continued through Day 3 <input type="checkbox"/> Continue IV PCA	<input type="checkbox"/> Consider D/C PCA (after lunch) <input type="checkbox"/> Gabapentin 300 mg PO TID continued through Day 3 <input type="checkbox"/> Discontinue Ketoralac (if on it). Start Ibuprofen 600 mg PO q6h. <input type="checkbox"/> Transition to Oxycodone 5-15 mg PO q3h PRN
Labs / Tests / Procedures	<input type="checkbox"/> CBC & CMP @ 0500	<input type="checkbox"/> CBC, CMP & Serum Amylase @ 0500
Fluids	<input type="checkbox"/> D5LR or LR or 0.45% NS, unless tachycardic or low UOP	<input type="checkbox"/> HLIV
Diet	<input type="checkbox"/> Advance to General Diet if tolerating CLD	<input type="checkbox"/> General Diet
Lines / Tubes / Drains	<input type="checkbox"/> Consider earlier removal of Foley for laparoscopic cases unless oliguric or continued catheterization indicated. DC Foley between 8 am and noon on POD 2 (standing order)	<input type="checkbox"/> Drain Amylase @ 0500
Mobility	<input type="checkbox"/> SCDs on except when ambulating; continue until discharge <input type="checkbox"/> OOB 6 hours per day and for all meals <input type="checkbox"/> Walk 3-4 times in the hall, goal 1-1.5 mile on unit	<input type="checkbox"/> SCDs on except when ambulating; continue until discharge <input type="checkbox"/> OOB 6 hours per day and for all meals <input type="checkbox"/> Walk 3-4 times in the hall, goal 1-1.5 mile on unit <input type="checkbox"/> Order DME (walker, cane, etc.)
Consults / Teaching	<input type="checkbox"/> Pharmacy Consult (Lovenox teaching) <input type="checkbox"/> Nutrition Consult (Diet education)	<input type="checkbox"/> Discuss diabetic education with nutrition and pharmacy i.e. insulin regimen <input type="checkbox"/> Consult Hyperglycemic Team if blood sugars uncontrolled or patient is new to insulin
Expected Outcomes		<input type="checkbox"/> Secure lodging arrangement (discuss with social work) <input type="checkbox"/> Review PT/OT recs. Assess for SNF or Home Health needs. <input type="checkbox"/> Med recon day before discharge

Fig 4. Whipple Post-operative Pathway Days 2–3.

<https://doi.org/10.1371/journal.pone.0209608.g004>

complication tracked by NSQIP other than superficial surgical site infection including cardiac, respiratory, and renal dysfunction as well as infection.

Univariate analysis was conducted with Student’s t-test, Kruskal Willis H-test, and chi-square test as appropriate for normally-distributed continuous, non-normally distributed continuous, and categorical variables, respectively. In order to control for differences between patients pre- and post-pathway implementation, we applied multivariate analysis. We selected, a priori, variables thought clinically to be associated with hospital LoS. We also included variables that were significantly associated on univariate analysis with the outcome of LoS ≤5 days. We performed regression analysis to estimate the association of the PD pathway with LoS ≤5 days. We explored nested models using likelihood ratio testing. Analyses were performed with IBM SPSS Statistics 22 and Stata IC v14.0 (StataCorp, College Station, Tx).

Results

A total of 145 patients underwent PD during the course of this study, 81 pre- and 64 post-pathway implementation. Complete 30-day follow up information was available for 139 (96%) patients, and 90 day follow up was available for 128 (88%) with the others being lost to follow up. Average age was similar pre- and post-pathway implementation (63.8 vs. 63.5 years, $p = 0.35$) (Table 1). The majority of operations were performed for pancreatic adenocarcinoma in both groups (61% vs. 65%, $p = 0.33$) and there was no difference in percentage needing vascular resection (28% vs. 34%, $p = 0.44$). The groups were largely similar in the rate of preoperative comorbidities including COPD (9% vs. 3%, $p = 0.18$) and diabetes (21% vs. 20%, $p = 0.92$),

Inpatient Milestones: 7SA Target Post-Op LOS = 3-5 days		
	Day 4	Day 5
Vitals / Monitoring	<input type="checkbox"/> Weigh daily until d/c <input type="checkbox"/> Incentive Spirometer: 10x/hr while awake until d/c <input type="checkbox"/> I&O's q8h	
Medications	<input type="checkbox"/> If still >5kg over pre-op weight give Lasix 10 mg IV. If inadequate response, give Lasix 20 mg IV <input type="checkbox"/> If no bowel movement to date, administer suppository or enema (as preferred by patient)	
Pain Note: APS orders all pain meds except PO/IV acetaminophen		
Labs / Tests / Procedures	<input type="checkbox"/> Consider D/C labs if stable (especially LFTs)	
Fluids		
Diet	<input type="checkbox"/> General Diet	
Lines / Tubes / Drains	<input type="checkbox"/> Consider removing drain if Drain Amylase is <3 x Serum Amylase or <318 (whichever is greater)	
Mobility	<input type="checkbox"/> SCDs on except when ambulating; continue until discharge <input type="checkbox"/> OOB 6 hours per day and for all meals <input type="checkbox"/> Walk 3-4 times in the hall, goal 1-1.5 mile on unit	
Consults / Teaching	<input type="checkbox"/> Shower with OT	
Expected Outcomes	<input type="checkbox"/> Prepare discharge (Med recon, send prescription, complete inpatient DC form, and confirm F/U in 1-2 weeks) <input type="checkbox"/> Med recon on the day before discharge	<input type="checkbox"/> Goals for D/C (tolerate diet, pain controlled, return of bowel function, ambulate safely, diabetic and pharmacy education completed (if indicated)) <input type="checkbox"/> Follow-up appointment is schedule for 1-2 weeks from now <input type="checkbox"/> D/C home or to local hotel if patient lives > 2 hrs from Seattle <input type="checkbox"/> Referral to outpatient dietician for patients with poor PO intake/continue to lose weight <input type="checkbox"/> Inpatient team communicate with outpatient team

Fig 5. Whipple Post-operative Pathway Days 4–5.

<https://doi.org/10.1371/journal.pone.0209608.g005>

however there was a higher rate of insulin use in the pre-pathway group ($p = 0.04$). There was no significant difference in CKD between groups as defined by $GFR < 60 \text{ ml/min/1.73m}^2$ (6% vs. 0%, $p = 0.29$), but there were more cardiac stents placed in the post-pathway group (2% vs. 13%, $p = 0.02$). Comorbidity and functional scoring via American Society of Anesthesiologists physical status classification (ASA) (22% vs. 29% ≤ 2 , $p = 0.37$) and Eastern Cooperative Oncology Group (ECOG) performance status (82% vs 91% ≤ 1 , $p = 0.06$) were not significantly different between the two groups. Pre-operative albumin levels $< 3.5 \text{ g/dL}$ were not different pre- and post-pathway implementation (34% vs 29%, $p = 0.61$). There was no significant difference in the proportion of patients who had neoadjuvant chemotherapy pre- and post-pathway implementation (26% vs. 38%, $p = 0.14$), but there was an increase in the use of neoadjuvant radiation post-pathway (14% vs. 28%, $p = 0.03$). Percentage of patients requiring vascular resections was not different before and after pathway implementation (28% vs. 34%, $p = 0.44$). Epidurals (44% vs. 8%, $p < 0.001$) and NG tubes (22% vs. 8%, $p = 0.02$) were placed intra-operatively more commonly before pathway implementation.

The proportion of patients discharging by a target of ≤ 5 days was nearly two times higher post-pathway implementation (36% vs. 64%, $p = 0.001$) for a median LoS of 5 days post pathway compared to 6 days pre-pathway (Table 2). Serious adverse events (SAEs) were similar between both the pre- and post-pathway groups (27% vs. 34%, $p = 0.34$). Rate of pancreatic leak grade B or C by ISGPS definition (29% vs. 27% $p = 0.35$) did not reach statistical significance²¹. Discharge to location other than home was not significantly different post after pathway implementation (7% vs. 3%, $p = 0.26$). Readmission within 30 days (20% pre- vs. 22% post-pathway ($p = 0.75$)) and 90 days (27% pre- vs. 36% post-pathway ($p = 0.27$)) were not significantly different, nor was the number of days from discharge to readmission was

Table 1. Demographics, clinical characteristics, and outcomes of patients before and after PD pathway implementation.

	Before Pathway (n = 81)	After Pathway (n = 64)	All patients (n = 145)	p-value
Demographics				
Mean age, years (SD)	63.3 (11.2)	63.5 (9.6)	63.4 (10.5)	0.35
Female, n (%)	40 (49)	36 (56)	76 (52)	0.41
Clinical characteristics				
Mean BMI, kg/m ² (SD)	26.9 (5.9)	25.8 (4.8)	26.4 (5.4)	0.33
Mean smoking pack years (SD)	10.9 (21.3)	9.2 (18.7)	10.1 (20.1)	0.78
Diabetes, n (%)	17 (21)	13 (20)	30 (20)	0.92
Previous cardiac stent (%)	2 (2)	8 (13)	10 (7)	0.02
CKD, n (%)	4 (6)	0 (0)	4 (4)	0.29
Hypoalbuminemia <3.5 g/dL, n (%)	20 (34)	10 (29)	30 (32)	0.61
ECOG performance status, n (%)				0.06
0	26 (55)	22 (40)	48 (47)	
1–2	19 (40)	33 (60)	52 (51)	
≥3	2 (4)	0 (0)	2 (2)	
ASA class, n (%)				0.370
1	1 (1)	0 (0)	1 (1)	
2	17 (21)	19 (30)	36 (25)	
≥3	63 (78)	45 (70)	108 (74)	
Neoadjuvant chemotherapy, n (%)	21 (26)	24 (38)	45 (31)	0.14
Neoadjuvant radiation, n (%)	11 (14)	18 (28)	29 (20)	0.03
Pre-operative epidural, n (%)	36 (44)	5 (8)	41 (28)	< 0.001
Mean IV fluid in OR, mL (SD)	5,710 (1,971)	4,866 (2,297)	5,337 (2,155)	0.01
Blood transfusion in OR, n (%)	7 (8)	11 (17)	18 (12)	0.12
Mean EBL in OR, mL (SD)	451.7 (860.6)	451.3 (622.8)	451.6 (762.4)	0.99
Soft pancreatic texture, n (%)	31 (45)	22 (36)	53 (41)	0.30
Pancreatic duct <3mm, n (%)	24 (33)	22 (35)	46 (34)	0.79
Primary outcome				
LOS ≤5 days, n (%)	29 (36)	41 (64)	70 (48)	0.001
Secondary outcomes				
ICU admission POD1, n (%)	10 (12)	9 (14)	19 (13)	0.81
Serious adverse event, n (%)	22 (27)	22 (34)	44 (30)	0.34
ISGPS 2016 grade B leak, n (%)	19 (23)	10 (16)	29 (20)	0.28
ISGPS 2016 grade C leak, n (%)	5 (6)	7 (11)	12 (8)	0.27
Delayed gastric emptying grade B or C, n (%)	17 (21)	10 (16)	27 (18)	0.46
Required TPN post-operatively, n (%)	16 (19)	8 (12)	24 (16)	0.27
Discharge to other place than home, n (%)	6 (7.4)	2 (3.1)	8 (5.5)	0.26
30 day readmission, n (%)	16 (20)	14 (22)	30 (21)	0.75
90 day readmission, n (%)	19 (27)	21 (36)	40 (31)	0.27

PD, Pancreaticoduodenectomy; SD, Standard deviation; BMI, Body mass index; CKD, Chronic kidney disease; ECOG, Eastern Cooperative Oncology Group performance status; ASA, American Society of Anesthesiologists physical status classification; LOS, Length of stay; ISGPS, International Study Group of Pancreatic Surgery; IV, Intravenous; OR, Operating room; EBL, Estimated blood loss

<https://doi.org/10.1371/journal.pone.0209608.t001>

significantly higher post-pathway implementation (day 30.4 vs. day 29.8, $p = 0.95$). Needing to be placed on total parenteral nutrition (TPN) (19% vs. 12%, $p = 0.27$) or having an NG tube placed in the post-operative period (after removal of the intra-operative NG if placed) (19.1% vs. 17.1%, $p = 0.69$) were not different between pre- or post-pathway groups. Rates of grade B

Table 2. Demographics, clinical characteristics, and outcomes of patients with LOS within goal of 5 days after PD or not.

	LoS ≤ 5 days (n = 70)	LoS ≥ 6 days (n = 75)	All patients (n = 145)	p-value
Demographics				
Mean age, years (SD)	64.0 (10.4)	62.8 (10.6)	63.4 (10.5)	0.16
Female, n (%)	36 (51)	40 (53)	76 (52)	0.81
Clinical characteristics				
Mean BMI, kg/m ² (SD)	25.6 (4.6)	27.2 (6.0)	26.4 (5.4)	0.13
Mean smoking pack years (SD)	6.5 (11.3)	13.5 (25.4)	10.1 (20.1)	0.20
Diabetes, n (%)	14 (20)	16 (21)	30 (20)	0.84
Previous cardiac stent (%)	7 (10)	3 (4)	10 (7)	0.19
CKD, n (%)	1 (2)	3 (5)	4 (4)	0.62
Hypoalbuminemia <3.5 g/dL, n (%)	8 (19)	22 (44)	30 (32)	0.01
ECOG performance status, n (%)				0.36
0	26 (51)	22 (43)	48 (47)	
1–2	25 (49)	27 (53)	52 (51)	
≥3	0 (0)	2 (4)	2 (2)	
ASA class, n (%)				0.43
1	1 (1)	0 (0)	1 (1)	
2	18 (26)	18 (24)	36 (25)	
≥3	51 (73)	57 (76)	108 (74)	
Neoadjuvant chemotherapy, n (%)	17 (24)	28 (37)	45 (31)	0.09
Neoadjuvant radiation, n (%)	14 (20)	15 (20)	29 (20)	1.00
Preop epidural, n (%)	13 (18)	28 (37)	41 (28)	0.01
Mean IV fluid in OR, mL (SD)	4,718 (2,023)	5,915 (2,126)	5,337 (2,155)	0.001
Blood transfusion in OR, n (%)	8 (11)	10 (13)	18 (12)	0.72
Mean EBL in OR, mL (SD)	433.3 (932.4)	468.6 (565.4)	451.6 (762.4)	0.78
Soft pancreatic texture, n (%)	25 (37)	28 (45)	53 (41)	0.40
Pancreatic duct <3mm, n (%)	22 (31)	24 (37)	46 (34)	0.46
Secondary outcomes				
ICU admission POD1, n (%)	2 (3)	17 (22)	19 (13)	< 0.001
Serious adverse event, n (%)	14 (20)	30 (40)	44 (30)	0.009
ISGPS 2016 grade B leak, n (%)	*9 (12)	20 (27)	29 (20)	0.03
ISGPS 2016 grade C leak, n (%)	*3 (4)	9 (12)	12 (8)	0.08
Delayed gastric emptying grade B or C, n (%)	*5 (7)	22 (30)	27 (18)	< 0.001
Required TPN post-op, n (%)	*4 (5)	20 (27)	24 (16)	0.001
Discharge to other place than home, n (%)	0 (0.0)	8 (10.6)	8 (5.5)	0.005
30 day readmission, n (%)	13 (19)	17 (23)	30 (21)	0.68
90 day readmission, n (%)	20 (32)	20 (30)	40 (31)	0.81

* All diagnosed during readmission

PD, Pancreaticoduodenectomy; SD, Standard deviation; BMI, Body mass index; CKD, Chronic kidney disease; ECOG, Eastern Cooperative Oncology Group performance status; ASA, American Society of Anesthesiologists physical status classification; LOS, Length of stay; ISGPS, International Study Group of Pancreatic Surgery; IV, Intravenous; OR, Operating room; EBL, Estimated blood loss

<https://doi.org/10.1371/journal.pone.0209608.t002>

or C DGE by ISGPS criteria (21% vs. 16%, $p = 0.46$) were not different pre- to post-pathway [22]. Of note, 5 patients pre-pathway and 2 patients post pathway included in the DGE cohort were tolerating a solid diet, but were made NPO and started on TPN due to a persistent pancreatic leak. Looking only at patients without any post-operative SAEs, 24 of 59 pre-pathway patients (41%) were discharged in 5 days or less for a median LoS of 6 days (mean 6.5). Post-

pathway, 22 of 42 patients without post-operative SAEs (52%) were discharged by goal of 5 days or less for a median LoS of 5 days (mean 5.0). The difference in reaching goal LoS between the pre-and post-pathway groups remain significant with $p < 0.001$ without increase in readmission within 30 days of surgery ($p = 0.93$).

The 30-day readmission rates of all patients discharged ≤ 5 days after surgery ($n = 70$) was similar that of patients discharged ≥ 6 days following surgery ($n = 75$; 19% vs. 23%; $p = 0.68$). There remained no significant difference in 90 day readmission after surgery for those discharged in ≤ 5 days or ≥ 6 days (32% vs. 30%, $p = 0.81$). Furthermore, the average date of readmission was similar between patients with LoS ≤ 5 and ≥ 6 (27.1 vs. 33.6 days; $p = 0.53$). LoS ≥ 6 days was associated with increased serious adverse events (20% vs. 40%, $p = 0.009$) and discharge to a location other than home (0% vs. 10%, $p = 0.005$). Looking at in-hospital risk factors for increased LoS, epidural placement was significantly associated with LoS ≥ 6 days (18% vs. 37%, $p = 0.01$). Intra-operative NG placement was higher in those with LoS ≥ 6 days (8% vs. 23%, $p = 0.018$) as was need for TPN (5% vs. 27%, $p = 0.001$) and grade B or C DGE (7% vs. 30%, $p < 0.001$). Pancreatic leak grade B or C by ISGPS criteria was also associated with LoS ≥ 6 days (17% vs. 39%, $p = 0.01$). All patients who were diagnosed with DGE or a grade B or C pancreatic leak but were discharged within goal LoS ≤ 5 were diagnosed upon their readmission. Pre-operative albumin < 3.5 g/dL was more frequent in those with LoS ≥ 6 days (19% vs. 44%, $p = 0.01$). Neither neoadjuvant chemotherapy (24% vs. 37%, $p = 0.09$), nor neoadjuvant radiation (20% vs. 20%, $p = 1.0$) was more common among those discharged in ≥ 6 days. There was no association between requiring a vascular resection and reaching goal LoS of ≤ 5 days or not (28% vs. 33%, $p = 0.53$). Higher scoring on ASA ($p = 0.46$) and ECOG ($p = 0.36$) were not associated with prolonged LoS.

Multivariate regression analysis was performed to evaluate factors that influenced LoS independent of the perioperative pathway. After controlling for the presence of diabetes, ASA class, use of neoadjuvant chemotherapy, and epidural use, patients treated on the PD pathway had three-times greater odds of having length of stay ≤ 5 days (Odds ratio (OR) 3.03, 95% Confidence Interval (CI): 1.41–6.53, $p = 0.005$). On univariate analysis, serum albumin level < 3.5 g/dL was associated with longer length of stay and so when additionally controlling for hypoalbuminemia, the difference in length of stay was no longer significant (OR 2.07, 95% CI: 0.70–6.10, $p = 0.19$, likelihood ratio test $p < 0.001$). However, because more than a third of patients in this study did not have albumin levels drawn peri-operatively, this likely represents introduction of type 2 error.

Risk factors for readmission at 30 days included blood transfusion in the OR (26.6% readmitted vs. 8.8% not, $p = 0.009$) as well as expected post-operative complications of any SAE, grade B or C pancreatic leak, DGE or need for TPN, and discharge to a place other than home (Table 3). Interestingly, ASA class was also a significant factor on univariate analysis, however there was a higher percentage of patients with ASA class 3 or greater in those who were not readmitted within 30 days. The significance of ASA class was not present for 90 day readmission, however, but both blood transfusion in the OR (25.0% readmitted vs. 9.0% not) as well as OR duration in minutes (519.6 vs. 438.9, $p = 0.002$) were significant (Table 4). Secondary outcomes of any SAE, grade B or C pancreatic leak, DGE or need for TPN, and discharge to a place other than home remained significant predictors of readmission at 90 days.

Discussion

This study demonstrates that our LoS of 5 days after pathway implementation is significantly shorter than our LoS prior to pathway initiation, as well as the NSQIP median of 8 days [5,23]. Equally as important, there was no significant increase in readmission rates at 30 and 90 days

Table 3. Demographics, clinical characteristics, and outcomes of patients readmitted within 30 days of surgery.

	Readmitted within 30 days (n = 30)	Not readmitted within 30 days (n = 113)	p-value
Demographics			
Mean age, years (SD)	62.2 (9.6)	63.4 (10.6)	0.56
Female, n (%)	15 (50.0)	59 (52.2)	0.82
Clinical characteristics			
Mean BMI, kg/m ² (SD)	27.4 (5.2)	26.3 (5.5)	0.31
Mean smoking pack years (SD)	7.1 (12.0)	10.7 (21.9)	0.38
Diabetes, n (%)	6 (20.0)	24 (21.2)	0.88
Previous cardiac stent (%)	2 (6.6)	8 (7.0)	0.93
CKD, n (%)	0 (0.0)	4 (5.0)	0.35
Hypoalbuminemia <3.5 g/dL, n (%)	4 (26.6)	26 (34.2)	0.57
ECOG performance status, n (%)			0.88
0	10 (52.6)	38 (46.3)	
1–2	9 (47.3)	42 (51.2)	
≥3	0 (0.0)	2 (2.4)	
ASA class, n (%)			0.02
1	1 (3.3)	0 (0.0)	
2	8 (26.6)	28 (24.7)	
≥3	21 (70.0)	85 (75.2)	
Neoadjuvant chemotherapy, n (%)	9 (30.0)	35 (30.9)	0.91
Neoadjuvant radiation, n (%)	6 (20.0)	23 (20.3)	0.96
Preop epidural, n (%)	7 (23.3)	34 (30.0)	0.46
Mean OR duration, minutes (SD)	493.6 (159.8)	455.7 (127.6)	0.17
Mean IV fluid in OR, mL (SD)	5,697 (2,496)	5,255 (2,067)	0.32
Blood transfusion in OR, n (%)	8 (26.6)	10 (8.8)	0.009
Mean EBL in OR, mL (SD)	503.3 (761.6)	442.5 (771.2)	0.70
Soft pancreatic texture, n (%)	13 (44.8)	39 (39.7)	0.62
Pancreatic duct <3mm, n (%)	11 (37.9)	35 (33.6)	0.66
Secondary outcomes			
ICU admission POD1, n (%)	5 (16.6)	13 (11.5)	0.44
Serious adverse event, n (%)	23 (76.6)	21 (18.5)	< 0.001
ISGPS 2016 grade B leak, n (%)	13 (44.8)	16 (14.2)	< 0.001
ISGPS 2016 grade C leak, n (%)	6 (20.6)	6 (5.3)	0.008
Delayed gastric emptying grade B or C, n (%)	15 (51.7)	12 (10.7)	< 0.001
Required TPN post-op, n (%)	13 (44.8)	11 (9.8)	< 0.001
Discharge to other place than home, n (%)	5 (16.6)	3 (2.6)	0.003

PD, Pancreaticoduodenectomy; SD, Standard deviation; BMI, Body mass index; CKD, Chronic kidney disease; ECOG, Eastern Cooperative Oncology Group performance status; ASA, American Society of Anesthesiologists physical status classification; LOS, Length of stay; ISGPS, International Study Group of Pancreatic Surgery; IV, Intravenous; OR, Operating room; EBL, Estimated blood loss

<https://doi.org/10.1371/journal.pone.0209608.t003>

among those discharged by the goal of 5 days, indicating that patients were not discharged before medically ready. There was also no increase in serious adverse events, suggesting that the interventions involved in the perioperative pathway were safe. The reasons for our pathway’s success is likely multi-factorial as previous studies with ERAS protocols have demonstrated, but the importance of pre-operative counseling of patients and their families as well as buy-in from clinical staff cannot be overstated.

Table 4. Demographics, clinical characteristics, and outcomes of patients readmitted within 90 days of surgery.

	Readmitted within 90 days (n = 40)	Not readmitted within 90 days (n = 88)	p-value
Demographics			
Mean age, years (SD)	62.4 (9.9)	63.8 (10.5)	0.47
Female, n (%)	20 (50.0)	44 (50.0)	1.0
Clinical characteristics			
Mean BMI, kg/m ² (SD)	27.0 (4.8)	25.9 (5.1)	0.25
Mean smoking pack years (SD)	6.2 (10.9)	12.5 (23.9)	0.11
Diabetes, n (%)	8 (20.0)	20 (22.7)	0.72
Previous cardiac stent (%)	3 (7.5)	7 (7.9)	0.92
CKD, n (%)	0 (0.0)	3 (4.8)	0.26
Hypoalbuminemia <3.5 g/dL, n (%)	6 (25.0)	23 (38.3)	0.24
ECOG performance status, n (%)			0.77
0	13 (48.1)	30 (45.4)	
1–2	14 (51.8)	34 (51.5)	
≥3	0 (0.0)	2 (3.0)	
ASA class, n (%)			0.23
1	1 (2.5)	0 (0.0)	
2	9 (22.5)	21 (23.8)	
≥3	30 (75.0)	67 (76.1)	
Neoadjuvant chemotherapy, n (%)	17 (42.5)	25 (28.4)	0.11
Neoadjuvant radiation, n (%)	11 (27.5)	16 (18.1)	0.23
Preop epidural, n (%)	11 (27.5)	28 (31.8)	0.62
Mean OR duration, minutes (SD)	519.6 (181.6)	438.9 (104.3)	0.002
Mean IV fluid in OR, mL (SD)	5,829 (2,700)	5,126 (1,864)	0.09
Blood transfusion in OR, n (%)	10 (25.0)	8 (9.0)	0.01
Mean EBL in OR, mL (SD)	676.2 (1,309)	384.4 (386.8)	0.06
Soft pancreatic texture, n (%)	22 (56.4)	47 (63.5)	0.46
Pancreatic duct <3mm, n (%)	14 (35.8)	27 (34.1)	0.85
Secondary outcomes			
ICU admission POD1, n (%)	7 (17.5)	11 (12.5)	0.45
Serious adverse event, n (%)	26 (65.0)	17 (19.3)	<0.001
ISGPS 2016 grade B leak, n (%)	13 (33.3)	14 (16.0)	0.02
ISGPS 2016 grade C leak, n (%)	7 (17.9)	5 (5.7)	0.03
Delayed gastric emptying grade B or C, n (%)	16 (41.0)	9 (10.3)	<0.001
Required TPN post-op, n (%)	14 (35.8)	8 (9.1)	<0.001
Discharge to other place than home, n (%)	5 (12.5)	2 (2.2)	0.01

PD, Pancreaticoduodenectomy; SD, Standard deviation; BMI, Body mass index; CKD, Chronic kidney disease; ECOG, Eastern Cooperative Oncology Group performance status; ASA, American Society of Anesthesiologists physical status classification; LOS, Length of stay; ISGPS, International Study Group of Pancreatic Surgery; IV, Intravenous; OR, Operating room; EBL, Estimated blood loss

<https://doi.org/10.1371/journal.pone.0209608.t004>

In previous studies that have examined pancreatic surgery patients from 2005 to 2015, median LoS has varied widely from 7–27 days [5,23–26]. Most studies were similarly limited to being single institution teaching hospitals, with study size varying from 40 to 255 patients [5,26]. While some studies have demonstrated a small sub-group of patients (up to 9%) that perform exceptionally well after surgery and are discharged in 5 days or less, our study demonstrates that the majority (64%) of patients achieve this milestone in the setting of our peri-

operative pathway[26]. Consistent with previous studies, we found no increase in readmission rates after earlier discharge[5,23,26].

Evaluating factors that were significantly related to LoS in previous studies, ASA class and ECOG score were not associated with attaining goal discharge in our patient population[27]. However, via multivariate analysis, pre-operative albumin level was found to be a significant predictor of meeting goal LoS. This correlation between lower albumin and longer LoS is similar to previous studies looking at albumin levels in patients with pancreatic cancer who underwent resection without neoadjuvant therapy, as well as patients undergoing colorectal and cardiac surgery[28–33]. Most studies defined hypoalbuminemia as serum level below 3.45 or 3.5 g/dL, although one used less than 3.0 g/dL[28–32]. Our data suggest that patients with serum albumin <3.5 g/dL prior to PD are less likely to make the goal of discharge by POD 5 and may benefit from additional nutritional counseling and possible supplementation prior to undergoing the stress of surgery. While we did not use pre-operative albumin at our institution to delay surgery nor do we have data on patients who delayed surgery, all patients during pre-operative counseling are encouraged to drink arginine-rich supplements prior to surgery and focus on protein-rich nutrition. Some barriers to patients actually receiving the shakes included availability at pharmacies and insurance coverage. We do not have data on who was unable to obtain the specific shakes, and therefore approached this with an "intention to treat" mindset, but the emphasis on adequate protein and calorie nutrition before and after surgery was achieved regardless. Additionally, patients were encouraged to meet the criteria of walking 2 miles before surgery. Also in agreement with most previous studies, discharge within goal of 5 days was not influenced by neoadjuvant systemic chemotherapy or radiation[26,33–36].

Regarding intra-operative and post-operative factors, we did not see a difference in morbidity, readmission, or meeting discharge goal of 5 days in patients who underwent vascular reconstructions compared to those who did not unlike previous studies[14,37]. The placement and duration of NG tubes is widely discussed in many fast-track pathway with the goal of early post-operative feeding that has been shown in numerous studies to shorten the time to return of bowel function[10,15,38–40]. Intra-operative NG tube placement did decrease following pathway implementation although they were still placed in some cases by surgeon judgment. Additionally, NG tubes were placed post-operatively if indicated in the setting of prolonged ileus or delayed gastric emptying as appropriate, but these rates did not differ pre- and post-pathway which, along with unchanged pancreatic leak rate, suggests no significant changes in surgical techniques were made during pathway implementation. Fluid overload has also been shown to increase morbidity and LoS after PD due to pulmonary complications and increased ileus as mentioned above, and thus the increase in early enteral feeding and decrease in intravenous fluids was strictly regulated in our pathway[17,41,42]. Avoidance of TPN if at all possible contributes to meeting fluid goals and decreasing infectious risks, and there was no difference in initiating TPN after pathway implementation.

Interestingly, while epidural use is promoted in many colorectal pre-operative pathways, including at our institution, their use for PD patients has been decreasing since early 2015. This preference against epidurals has grown without explicit direction from the perioperative pathway stakeholders, however it may influence our results associating epidurals with increased risk of not discharging by POD 5. In contrast, a previously reported single institution study examining Whipple patients with LoS ≤ 5 days found a shorter LoS was associated with higher rates of epidural placement[25]. Additionally, other studies examining pain control and respiratory complications after pancreaticoduodenectomy have shown benefits to epidural placement, although some did note slightly increased LoS[15,43–45]. However, it has been shown that ineffective epidurals often lead to decreased pain control and therefore decreased patient mobility post-operatively[44–46]. Additionally, hypotension associated with epidural

use can lead to increased IV fluid administration and increased LoS[46]. It is possible that interventions to correct hypotension or only partial pain control with some epidurals led to a longer LOS in our study. Successful pain control and avoidance of complications with epidural analgesia is likely to be highly dependent on institutional experience with catheter placement.

All of our patients had a drain placed near the site of the pancreaticojejunostomy intra-operatively. Drain fluid amylase was routinely checked prior to pathway initiation, but this was standardized to POD 1 and POD 3 with the pathway. Drains were removed on POD 3–4 if the fluid amylase was <3 times the higher of the serum amylase or the upper limit of normal and there was no concern for leak based on appearance of the output. Using the ISGPS definition of pancreatic leak, which has been found to predict LoS > 10 days in previous studies, we did find a significant association with grade B or C leak and LoS within goal of 5 days or readmission; many of these leaks were diagnosed upon readmission regardless of initial LOS, however[21,47,48]. Patients with higher drain amylases on POD 3 may not have been discharged as readily for fear of development of a leak or need for additional teaching to go home with a drain, but there is the possibility that the drain was not appropriately functioning and readings could have been misleadingly low.

There are several limitations to our retrospective study. While we officially adopted the perioperative pathway on June 1st, 2015, it is possible that culture change occurred prior to actual pathway initiation that may have influenced the study results. Additionally, epidural placement strongly declined during the months prior to pathway implementation. While this was not part of the pathway design, it inadvertently changed patient management outside of the pathway that had an effect in univariate analysis.

Conclusions

The coordination of our peri-operative care system helps set patient expectations and optimize care after pancreaticoduodenectomy. With this investment from all members of the care team, LoS has been lowered to a median of 5 days without compromising safety. Further improvements may be achieved by aggressively optimizing nutrition prior to surgery.

Supporting information

S1 Fig. Care map for patients.

(PDF)

Acknowledgments

We would like to acknowledge our entire perioperative care team and all who were instrumental in development of the PD pathway.

Author Contributions

Conceptualization: Sara K. Daniel, Venu G. Pillarisetty.

Data curation: Sara K. Daniel.

Formal analysis: Sara K. Daniel, Lucas W. Thornblade.

Supervision: Venu G. Pillarisetty.

Writing – original draft: Sara K. Daniel.

Writing – review & editing: Sara K. Daniel, Lucas W. Thornblade, Gary N. Mann, James O. Park, Venu G. Pillarisetty.

References

1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic Cancer. *Lancet*. 2016 Jul; 388(10039):73–85. [https://doi.org/10.1016/S0140-6736\(16\)00141-0](https://doi.org/10.1016/S0140-6736(16)00141-0) PMID: 26830752
2. Bednar F, Simeone DM. Recent advances in pancreatic surgery. *Curr Opin Gastroenterol*. 2014 Sep; 30(5):518–23. <https://doi.org/10.1097/MOG.0000000000000096> PMID: 25010685
3. Ansoorge C, Lindström P, Strömmer L, Blomberg J, Lundell L, Andrén-Sandberg A, et al. Assessing surgical quality: comparison of general and procedure-specific morbidity estimation models for the risk adjustment of pancreaticoduodenectomy outcomes. *World J Surg*. 2014 Sep; 38(9):2412–21. <https://doi.org/10.1007/s00268-014-2554-7> PMID: 24705780
4. Fernandez-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP, et al. Evolution of the Whipple Procedure at the Massachusetts General Hospital. *Surgery* 2012 Sep; 152(3 Suppl 1):S56–63.
5. Hall TC, Dennison AR, Bilku DK, Metcalfe MS, Garcea G. Enhanced recovery programmes in hepatobiliary and pancreatic surgery: a systematic review. *Ann R Coll Surg Engl*. 2012 Jul; 94(5):318–26. <https://doi.org/10.1308/003588412X13171221592410> PMID: 22943226
6. Howard JM. Development and progress in resective surgery for pancreatic cancer. *World J Surg*. 1999 Sep; 23(9):901–6. PMID: 10449818
7. Pillai SA, Palaniappan R, Pichaimuthu A, Rajendran KK, Sathyasesan J, Govindhan M. Feasibility of implementing fast-track surgery in pancreaticoduodenectomy with pancreaticogastrostomy for reconstruction—a prospective cohort study with historical control. *Int J Surg*. 2014; 12(9):1005–9. <https://doi.org/10.1016/j.ijsu.2014.07.002> PMID: 25014648
8. Balzano G, Zerbi A, Braga M, Rocchetti S, Beneduce AA, Di Carlo V. Fast-track recovery programme after pancreaticoduodenectomy reduces delayed gastric emptying. *Br J Surg*. 2008 Nov; 95(11):1387–93. <https://doi.org/10.1002/bjs.6324> PMID: 18844251
9. Kobayashi S, Ooshima R, Koizumi S, Katayama M, Sakurai J, Watanabe T, et al. Perioperative care with fast-track management in patients undergoing pancreaticoduodenectomy. *World J Surg*. 2014 Sep; 38(9):2430–7. <https://doi.org/10.1007/s00268-014-2548-5> PMID: 24692004
10. Zouros E, Liakakos T, Machairas A, Patapis P, Agalianos C, Dervenis C. Improvement of gastric emptying by enhanced recovery after pancreaticoduodenectomy. *Hepatobiliary Pancreat Dis Int*. 2016 Apr; 15(2):198–208. PMID: 27020637
11. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. *Ann Surg*. 2008 Aug; 248(2):189–98. <https://doi.org/10.1097/SLA.0b013e31817f2c1a> PMID: 18650627
12. Ypsilantis E, Praseedom RK. Current status of fast-track recovery pathways in pancreatic surgery. *JOP*. 2009 Nov 5; 10(6):646–50. PMID: 19890186
13. Nikfarjam M, Weinberg L, Low N, Fink MA, Muralidharan V, Houli N, et al. A fast track recovery program significantly reduces hospital length of stay following uncomplicated pancreaticoduodenectomy. *JOP*. 2013 Jan 10; 14(1):63–70. <https://doi.org/10.6092/1590-8577/1223> PMID: 23306337
14. Nussbaum DP, Penne K, Stinnett SS, Speicher PJ, Cocieru A, Blazer DG 3rd, et al. A standardized care plan is associated with shorter hospital length of stay in patients undergoing pancreaticoduodenectomy. *J Surg Res*. 2015 Jan; 193(1):237–45. <https://doi.org/10.1016/j.jss.2014.06.036> PMID: 25062813
15. Lassen K, Coolsen MM, Slim K, Carli F, de Aguilar-Nascimento JE, Schäfer M, et al. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(R)) society recommendations. *World J Surg*. 2013 Feb; 37(2):240–58. <https://doi.org/10.1007/s00268-012-1771-1> PMID: 22956014
16. Eshuis WJ, Hermanides J, van Dalen JW, van Samkar G, Busch OR, van Gulik TM, et al. Early postoperative hyperglycemia is associated with post-operative complications after pancreatoduodenectomy. *Ann Surg*. 2011 Apr; 253(4):739–44. <https://doi.org/10.1097/SLA.0b013e31820b4bfc> PMID: 21475014
17. Myles P, Bellomo R, Corcoran T, Forbes A, Wallace S, Peyton P et al. Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF): rationale and design for a multicentre randomised trial. *BMJ Open*. 2017 Mar 3; 7(3):e015358. <https://doi.org/10.1136/bmjopen-2016-015358> PMID: 28259855
18. Hashimoto D, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Yamamura K, et al. Efficacy and safety of postoperative anticoagulation prophylaxis with enoxaparin in patients undergoing pancreatic surgery: A prospective trial and literature review. *Pancreatology*. 2017 May-Jun; 17(3):464–470. <https://doi.org/10.1016/j.pan.2017.03.010> PMID: 28366422
19. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med*. 2002 Mar 28; 346(13):975–80. <https://doi.org/10.1056/NEJMoa012385> PMID: 11919306

20. American College of Surgeons. User Guide for the 2015 ACS NSQIP Participant Use Data File. https://www.facs.org/~media/files/quality%20programs/nsqip/nsqip_puf_user_guide_2015.ashx. Accessed May 17, 2017.
21. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. *Surgery*. 2017 Mar; 161(3):584–591. <https://doi.org/10.1016/j.surg.2016.11.014> PMID: 28040257
22. Cusworth BM, Krasnick BA, Nywening TM, Woolsey CA, Fields RC, Doyle MM, et al. Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. *HPB (Oxford)*. 2017 Feb; 19(2):147–153.
23. Xiong J, Szatmary P, Huang W, de la Iglesia-Garcia D, Nunes QM, Xia Q, et al. Enhanced Recovery After Surgery Program in Patients Undergoing Pancreaticoduodenectomy: A PRISMA-Compliant Systemic Review and Meta-Analysis. *Medicine (Baltimore)*. 2016 May; 95(18):e3497.
24. Enomoto LM, Gusani NJ, Dillon PW, Hollenbeak CS. Impact of surgeon and hospital volume on mortality, length of stay, and cost of pancreaticoduodenectomy. *J Gastrointest Surg*. 2014 Apr; 18(4):690–700. <https://doi.org/10.1007/s11605-013-2422-z> PMID: 24297652
25. Schneider EB, Hyder O, Wolfgang CL, Dodson RM, Haider AH, Herman JM, et al. Provider versus patient factors impacting hospital length of stay after pancreaticoduodenectomy. *Surgery*. 2013 Aug; 154(2):152–61. <https://doi.org/10.1016/j.surg.2013.03.013> PMID: 23889945
26. Lee GC, Fong ZV, Ferrone CR, Thayer SP, Warshaw AL, Lillemoie KD, et al. High performing Whipple patients: Factors associated with short length of stay after pancreaticoduodenectomy. *J Gastrointest Surg* (2014) 18:1760–1769. <https://doi.org/10.1007/s11605-014-2604-3> PMID: 25091843
27. Young J, Badgery-Parker T, Dobbins T, Jorgensen M, Gibbs P, Faragher I, et al. Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. *J Pain Symptom Manage*. 2015 Feb; 49(2):258–64. <https://doi.org/10.1016/j.jpainsymman.2014.06.006> PMID: 24996034
28. Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, et al. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. *PLoS One*. 2016 Mar 25; 11(3):e0152172 <https://doi.org/10.1371/journal.pone.0152172> PMID: 27015568
29. El-Hussuna A, Ilesalnieks I, Horesh N, Hadi S, Dreznik Y, Zmora O. The effect of pre-operative optimization on post-operative outcome in Crohn's disease resections. *Int J Colorectal Dis*. 2017 Jan; 32(1):49–56. <https://doi.org/10.1007/s00384-016-2655-x> PMID: 27785551
30. Gohil R, Rishi M, Tan BH. Pre-operative serum albumin and neutrophil-lymphocyte ratio are associated with prolonged hospital stay following colorectal surgery. *Br J Med Med Res*. 2014 Jan 1; 4(1):481–487. <https://doi.org/10.9734/BJMMR/2014/5444> PMID: 24278850
31. Koertzen M, Punjabi P, Lockwood G. Pre-operative serum albumin concentration as a predictor of mortality and morbidity following cardiac surgery. *Perfusion*. 2013 Sep; 28(5):390–4. <https://doi.org/10.1177/0267659113488990> PMID: 23722638
32. Lohsiriwat V, Lohsiriwat D, Boonnuch W, Chinswangwatanakul V, Akaraviputh T, Lert-Akayamanee N. Pre-operative hypoalbuminemia is a major risk factor for post-operative complications following rectal cancer surgery. *World J Gastroenterol*. 2008 Feb 28; 14(8):1248–51. <https://doi.org/10.3748/wjg.14.1248> PMID: 18300352
33. Greenblatt DY, Kelly KJ, Rajamanickam V, Wan Y, Hanson T, Rettammel R, et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. *Ann Surg Oncol*. 2011 Aug; 18(8):2126–35. <https://doi.org/10.1245/s10434-011-1594-6> PMID: 21336514
34. Mirkin KA, Hollenbeak CS, Gusani NJ, Wong J. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. *Am J Surg*. 2016 Sep 6. Epub ahead of print
35. Cho SW, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, et al. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). *HPB (Oxford)*. 2014 Apr; 16(4):350–6.
36. Percorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, et al. Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. *J Gastrointest Surg*. 2013 Mar; 17(3):488–93. <https://doi.org/10.1007/s11605-012-2063-7> PMID: 23132627
37. Kantor O, Talamonti MS, Sharpe S, Lutfi W, Winchester DJ, Roggin KK, et al. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. *Am J Surg*. 2017 Mar; 213(3):512–515. <https://doi.org/10.1016/j.amjsurg.2016.10.030> PMID: 28049562
38. Rayar M, Sulpice L, Meunier B, Boudjema K. Enteral nutrition reduces delayed gastric emptying after standard pancreaticoduodenectomy with child reconstruction. *J Gastrointest Surg*. 2012 May; 16(5):1004–11. <https://doi.org/10.1007/s11605-012-1821-x> PMID: 22258876

39. Cunningham KE, Zenati MS, Petrie JR, Steve JL, Hogg ME, Zeh HJ 3rd, et al. A policy of omitting an intensive care unit stay after robotic pancreaticoduodenectomy is safe and cost-effective. *J Surg Res*. 2016 Jul; 204(1):8–14 <https://doi.org/10.1016/j.jss.2016.04.023> PMID: 27451861
40. Benrem DJ, Yeh JJ, Brennan MF, Kiran R, Pastores SM, Halpern NA, et al. Predictors of intensive care unit admission and related outcome for patients after pancreaticoduodenectomy. *J Gastrointest Surg*. 2005 Dec; 9(9):1307–12. <https://doi.org/10.1016/j.gassur.2005.09.010> PMID: 16332487
41. Weinberg L, Wong D, Karalpillai D, Pearce B, Tan CO, Tay S, et al. The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple's procedure). *BMC Anesthesiol*. 2014 May 14; 14:35. <https://doi.org/10.1186/1471-2253-14-35> PMID: 24839398
42. Wright GP, Koehler TJ, Davis AT, Chung MH. The drowning whipple: perioperative fluid balance and outcomes following pancreaticoduodenectomy. *J Surg Oncol*. 2014 Sep; 110(4):407–11. <https://doi.org/10.1002/jso.23662> PMID: 24861716
43. Amini N, Kim Y, Hyder O, Spolverato G, Wu CL, Page AJ, et al. A nationwide analysis of the use and outcomes of perioperative epidural analgesia in patients undergoing hepatic and pancreatic surgery. *Am J Surg*. 2015 Sep; 210(3):483–91. <https://doi.org/10.1016/j.amjsurg.2015.04.009> PMID: 26105799
44. Shah DR, Brown E, Russo JE, Li CS, Martinez SR, Coates JM, et al. Negligible effect of perioperative epidural analgesia among patients undergoing elective gastric and pancreatic resections. *J Gastrointest Surg*. 2013 Apr; 17(4):660–7. <https://doi.org/10.1007/s11605-013-2142-4> PMID: 23345053
45. Choi DX, Schoeniger LO. For patients undergoing pancreaticoduodenectomy, epidural anesthesia and analgesia improves pain but increases rates of intensive care unit admissions and alterations in analgesics. *Pancreas*. 2010 May; 39(4):492–7. <https://doi.org/10.1097/MPA.0b013e3181bdfc76> PMID: 19959965
46. Pratt WB, Steinbrook RA, Maithel SK, Vanounou T, Callery MP, Vollmer CM. Epidural analgesia for pancreaticoduodenectomy: a critical appraisal. *J Gastrointest Surg*. 2008 Jul; 12(7):1207–20. <https://doi.org/10.1007/s11605-008-0467-1> PMID: 18264686
47. Hüttner FJ, Probst P, Knebel P, Strobel O, Hackert T, Ulrich A, Büchler et al. Meta-analysis of prophylactic abdominal drainage in pancreatic surgery. *Br J Surg*. 2017 May; 104(6):660–668. <https://doi.org/10.1002/bjs.10505> PMID: 28318008
48. Reid-Lombardo KM, Farnell MB, Crippa S, Barnett M, Maupin G, Bassi C, et al. Pancreatic anastomatic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomatic Leak Study Group. *J Gastrointest Surg*. 2007 Nov; 11(11):1451–8. <https://doi.org/10.1007/s11605-007-0270-4> PMID: 17710506